Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single ascending dose IV and SC CMK389 in Japanese healthy participants
jRCT2071210115Phase 1Completed
- Sponsor
- Novartis
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CMK-389 (8 cohorts), sponsored by Novartis. Primary endpoint: Safety endpoints. Started Feb 2022; status: completed.
02
Drugs
CMK-389
Beyond the preview
Go deeper on jRCT2071210115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210115.